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Description of the method for collecting evidence 
In order to elaborate this guideline, the following primary and 
secondary electronic databases were consulted: MEDLINE, 
Cochrane, Central Register of Controlled Trials – CENTRAL, 
Embase, and Lilacs. The search for evidence was based 
on real clinical settings, MeSH terms/descriptors and the 
following isolated terms were used: Anaphylaxis; Allergens; 
Anaphylatoxins; Mast Cells; Adult; Chymases; Serine 
Endopeptidases. The articles were selected after critical 
evaluation of scientific evidence strength by specialists from 
the participant societies, and the best publications were used 
for the recommendations. Recommendations were elaborated 
after a discussion within the group. The entire guideline was 
reviewed by an independent group specialized in evidence-
based clinical guidelines.
Degrees of recommendation and strength of evidence
A: Experimental or observational studies of higher consistency.
B: Experimental or observational studies of lesser consistency. 
C Case reports (non-controlled studies).
D: Opinions without critical evaluation, based on consensus, 
physiological studies, or animal models.
Objective
Anaphylaxis is a potentially fatal allergic reaction that can 
be triggered by various etiological agents. Clinical suspicion, 
along with the identification of etiology, is a fundamental point 
for safe and adequate approach of patients during an acute 
event. The etiology of anaphylaxis is varied according to age 
and especially to the area in which the reaction occurs. In this 
guideline, the main symptoms and clinical signs are discussed, 
in order to allow the diagnosis of an anaphylaxis event; its 
main etiological agents are also discussed.
Introduction
Anaphylaxis is known as a severe and acute allergic reaction 
presenting a sudden onset and rapid evolution, which is 
potentially fatal1(D). The target organs involved include the 
skin and mucosae membranes (80% to 90% of episodes), 
respiratory system (70%), gastrointestinal tract (30% to 40%), 
cardiovascular system (10% to 45%), and central nervous 
system (10% to 15%)1(D).
The cutaneous-mucosal manifestations consist of 
localized or diffused erythema, pruritus, rash, nettle-rash, 
and/or angioedema. Cutaneous manifestations are the most 
frequent, and usually arise early in anaphylaxis. In the 
respiratory system, pruritus and nasal congestion, sneezing, 
pruritus or tightening of the throat, disphony, hoarseness, 
stridor in the throat, coughing, wheezing, or dyspnea may 
occur. Manifestations in the gastrointestinal tract include 
nausea, vomiting, cramping, and diarrhea. The involvement 
of cardiovascular system may cause hypotension, whether or 
not presenting syncope; tachycardia; and cardiac arrhythmias. 
The neurological manifestations include cephalea, seizures, 
and changes in mental state. Other clinical manifestations 
can also occur, such as feeling of impending doom, uterine 
contractions, decrease in strength of sphincter muscles, loss 
of sight, and tinnitus2(D). 
There is an increasing attention concerning the importance 
of the heart as a target-organ in anaphylaxis. In the healthy 
human heart, mast cells are present in myocardium and in 
the intima of coronary arteries. In patients with coronary 
artery disease, mast cells are found in atherosclerotic lesions, 
and contribute to atherogenesis. Mast cells mediators, such 
as histamine, leukotriene C4, and prostaglandin D2 may 
lead to spasms of coronary arteries3(D). Thus, anaphylaxis 
can “unmask” a subclinical coronary disease and may cause 
myocardial infarction and/or arrhythmia, regardless of 
adrenaline use.
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The anaphylactic reaction usually occurs within seconds or 
minutes after exposure to a causative agent. However, some 
reactions can occur later. The episodes of anaphylaxis can 
have a sudden manifestation and be uniphasic; they may arise 
late (> 30 minutes), or be biphasic. In biphasic reactions, the 
immediate phase is followed by a period free of symptoms; 
posteriorly, the late reaction arises, and signs and symptoms 
upsurge, regardless of a new exposure to the triggering agent. 
The late phase occurs within eight to 12 hours after the 
immediate reaction, and it is present in approximately 20% 
of anaphylaxis cases. Biphasic reactions are more frequent in 
food-related anaphylaxis4(D).
The diagnosis of anaphylaxis is based on defined clinical 
criteria5(D). Anaphylaxis is highly likely when one of three 
criteria described in Box 1 is fulfilled.
1. What are the main triggers of anaphylaxis?
They are variable and dependent on patient’s age. 
Medications, certain foods, and insect venoms (Hymenoptera: 
bees, wasps, and ants) are the main triggers of anaphylaxis. 
Other common agents are latex (contained in medical 
devices, air balloons, condoms, among others) and physical 
stimulations, such as exercise and cold. Exercise-induced 
anaphylaxis can occur isolated or associated with previous 
ingestion of certain foods or medications. In some crises 
it is not possible to identify the causative agent,  thus 
characterizing idiopathic anaphylaxis2,6(D) (Box 1).
Analgesic, non-hormonal anti-steroidal drugs and 
antibiotics are types of medication that frequently cause 
anaphylaxis. In hospitalized patients, allergic reactions to 
antibiotics are predominant. In the surgical environment, 
anaphylactic reactions can be caused by neuromuscular 
blockers, latex, antibiotics, opiates, and anti-inflammatory 
drugs7(C) 2(D). In Brazil there is a prevalence of medication-
triggered anaphylaxis, followed by certain types of food and 
insects8(C).
The allergic sensitization towards food is dependent on 
genetic factors and eating habits. In childhood, the most 
important types of food in anaphylaxis are cow’s milk and 
egg white; for adults, mollusks and crustaceans. Sensitivity to 
fruits and vegetables presents lower incidence, although it can 
also induce intense reactions2,9(D).
The venom of bees, wasps, hornets, and ants can induce 
severe anaphylactic reactions. The sensitization arises after 
several contacts in which only local reactions are observed. 
Systemic reaction to insects is more common in beekeepers 
and their relatives, farmers and rural residents, rural 
professionals (veterinarians and agronomists), fruit growers, 
and outdoor recreationalists5,10(D).
Latex proteins in medical devices, toys, and condoms can 
induce severe clinical pictures of anaphylaxis in susceptible 
people. Atopy is a risk factor for latex sensitization. The clinical 
picture is more frequent among health care professionals 
who usually work using gloves, such as surgeons, nurses, 
and nursing technicians; children bearing spina bifida; and 
patients who have undergone multiple surgeries1,6(D). Latex 
allergens present antigenic determinants, which are found in 
numerous vegetables. In patients allergic to latex, it is common 
to observe an evolving sensitization to banana, kiwi, avocado, 
and cassava, among others1,6(D).
Physical stimuli such as cold air and physical exercise can 
activate mast cells and as a result cause anaphylaxis. In recent 
years, clinical pictures of anaphylaxis were more frequently 
identified, as they were caused by the association between 
physical exercise and previous ingestion of certain types of 
food or medication. Those reactions may be specific for a given 
type of food or drug, or may arise associated with the ingestion 
of any type of food or drug.2,10(D).
Recommendation
There are many etiologic factors that trigger the process 
of anaphylaxis. Some factors are associated with higher 
incidence, such as the nature of antigen and the history 
of atopy. Medicines are the agents that most frequently 
cause anaphylaxis, and the most common are analgesics, 
antipyretics, non-hormonal anti-inflammatory, and antibiotics.
2. How can the activation mechanisms of mast 
cells and basophils help to understand the phases 
of anaphylactic reactions?
The majority of triggering agents for anaphylaxis are related 
to the mechanism of immediate hypersensitivity mediated 
by immunoglobulin E (IgE), which results in the activation 
of mast cells and basophils11(B). However, several other 
immunological and non-immunological mechanisms can also 
cause the activation of these cells, and trigger acute reactions 
clinically similar to classical anaphylaxis, mediated by IgE. 
These mechanisms include the antigen-immunoglobulin G(IgG) 
complex, activation of the complement system, activation of the 
coagulation system, direct activation of mast cells and basophils, 
cytotoxicity, changes in the arachidonic acid metabolism, 
release of neuropeptides, physical exercises, and cold air and 
cold water. In some patients, the anaphylactic reactions can 
simultaneously have more than one active mechanism10(D).
Clinical experience and observational studies indicate that 
the main immunological mechanism in allergen-induced 
anaphylaxis is mediated by IgE. Therefore, based on studies 
with mice regarding experimental models of anaphylaxis to 
IgG-mediated penicillin, the possibility of activating basophils 
by complexes of IgG-allergens has been suggested, in patients 
with proven anaphylactic reaction to allergens (for instance, 
penicillin), who do not present evidence for specific IgE 
sensitization. It is still not clear whether the main effector cells 
from this way are the macrophages and/or basophils12,13(D). 
The cellular episodes that occur during the anaphylactic 
reaction involve the activation of tyrosine-kinases and 
calcium inflow into mast cells and basophils, resulting in a 
quick release of pre-formed mediators such as histamine, 
tryptase, carboxypeptidase A3, chymase, and proteoglycans. 
Later, the activation of  phospholipase A2, cyclooxygenase, and 
lipoxygenase occur, leading to the production of arachidonic 
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Box 1 – Criteria for diagnosing anaphylaxis.
1. Acute onset of disease (minutes or hours) with involvement of skin, mucosa, or both (for instance, generalized nettle-rash, pruritus or facial erythema, 
lips-tongue-uvula edema).
And at least one of the following items:
a) Respiratory impairment (dyspnea, wheezing-bronchospasm, stridor, decreased peak expiratory flow, hypoxia).
b) Low blood pressure or symptoms associated with organic dysfunction (for instance, hypotonia [collapse], syncope, incontinence).
2. Two or more of the following symptoms occurring shortly after exposure to a likely allergen for that patient (minutes to hours)
a) Involvement of skin-mucosa (for instance, generalized nettle-rash, pruritus or facial erythema, lips-tongue-uvula edema).
b) Respiratory impairment (dyspnea, wheezing-bronchospasm, stridor, decreased peak expiratory flow, hypoxia).
c) Drop in blood pressure or symptoms associated with organic dysfunction (for instance, hypotonia [collapse], syncope, incontinence).
d) Persistent gastrointestinal symptoms (for instance, persistent abdominal colic, vomiting).
3. Drop in blood pressure after exposure to a known allergen for that patient (minutes to hours): 
a) infants and young children: low systolic arterial pressure (age-specific) or a drop in the systolic arterial pressure > 30%
 b) Adults: systolic arterial pressure less than 90 mmHg or drop > 30% in basal systolic arterial pressure
acid metabolites, especially leukotrienes and prostaglandins, 
and a synthesis of platelet activating factor (PAF). In addition, 
several cytokines are released and synthesized, including 
IL-6, IL-33, and TNF-_, which take part in the late phase of 
anaphylaxis14(D).
Histamine is the critical mediator of symptoms arising in 
the immediate phase of anaphylaxis. In extracellular medium, 
histamine is quickly metabolized, presenting a half-life of 30 
minutes, which tends to limit its use as activating marker 
for mast cells and basophils. In anaphylaxis, histamine 
reaches plasmatic levels in 5 minutes, and remains high for 
30 to 60 minutes. Urinary histamine metabolites, including 
methylhistamine, can be detected up to 24 hours after the 
initiation of anaphylaxis15(D).
Tryptase is secreted as an active proteoglycans complex in 
a large size, limiting its diffusion of the activation site of mast 
cells to the circulation. Tryptase reaches serum peak levels 
in 60 to 90 minutes after the initiation of anaphylaxis and 
remains elevated for up to 5 hours. Tryptase can activate the 
kallikrein-kinin system, resulting in production of bradykinin 
and causing angioedema11(B),4(D).
Mast cells generate and release icosanoid l ipid 
mediators from cellular membrane phospholipids due to 
multiple enzymatic stages. Arachidonic acid is cleaved 
from cellular membrane phospholipids by phospholipase 
A2, and is subsequently metabolized by cyclooxygenase 
and lipoxygenase-5, which generate leukotrienes and 
prostaglandins, respectively. These mediators are released 
in the immediate phase within 10 minutes; prostaglandin 
is also synthesized in the late phase, resulting in a new 
release in 2 to 10 hours after the initial activity. The 
biological activities of leukotrienes include smooth muscle 
contraction, increased vascular permeability, vasodilation, 
mucus secretion, recruitment of inflammatory cells, 
cytokine productionmodulation, and changes in neuronal 
transmission14(D).
In anaphylaxis mediated by IgG, PAF appears to be the 
main mediator12(D). PAF is a potent vasoactive amine released 
by a large variety of cells including mast cells, basophils, 
endothelial cells, monocytes, and macrophages. Basophils, 
when stimulated by IgG allergens complexes, release PAF in 
much higher amounts as compared to other cellular sources of 
this mediator12(D).  PAF stimulates endothelial cells, resulting 
in increased vascular permeability; acts on bronchial smooth 
muscle, causing bronchoconstriction; and takes part in 
chemotaxis and in eosinophils and neutrophils activation14(D).
Mast cells and basophils release cytokines and 
chemokines, which mainly contribute to the late phase of 
biphasic anaphylactic reaction. The behavior of cytokines 
and chemokines results in recruitment and activation of cells 
involved in allergic inflammation, as well as in potentiation 
of the anaphylactic response. Activated mast cells release 
IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, IL-16, IL-18, IL-22, IL-33, 
TNF-_, and GM-CSF. Basophils are the main source of IL-4, 
IL-13, and chemokines. In anaphylaxis, IL-4 increases the 
responsiveness of target cells to vasoactive mediator action 
by three to six times including histamine, PAF, and cysteinic 
leukotrienes 14(D).
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Recommendation
Some studies indicate that the main immunological 
mechanism involved in induced anaphylaxis, as a consequence 
of allergenic sensitization, is mediated by production of IgE 
class specific antibodies, which results in the activation of 
mast cells and basophils and in a quick release of pre-formed 
mediators, such as histamine, tryptase, carboxypeptidase A3, 
chimase, and proteoglycans.
The dosage of mediators can be useful in establishing the 
diagnosis of anaphylaxis; the laboratory methods used are 
the dosage of serum tryptase levels, plasmatic histamine, 
and urinary methylhistamine. The best moment for tryptase 
dosage is within one or two hours after the initiation of 
anaphylactic reaction, while for histamine it is between ten 
minutes and one hour. Histamine urinary metabolites can 
remain high in urine for up to 24 hours.
3. Which factors increase the risk for anaphylaxis 
and severe anaphylactic reactions?
Diverse factors can increase the severity of an anaphylactic 
reaction or interfere in its treatment, thus making it 
potentially more severe1,10(D). The quick intravenous 
infusion of an allergen is associated with risks of more 
severe reactions. Older age or the presence of pre-existing 
cardiovascular disease are also risk factors for severe 
anaphylaxis. The presence of asthma is associated with more 
severe episodes, especially in reactions caused by allergy to 
certain types of food6,16(D).
The concomitant use of `-blocker agents by topic or oral 
pathways is associated with risks of most severe reactions 
due to the interference with the treatment of anaphylaxis. 
Epinephrine applied to individuals using `-blockers can 
theoretically lead to an isolated alpha-adrenergic effect, 
resulting in severe hypertension. However, these individuals, 
when receiving epinephrine for the hypotension caused by 
anaphylaxis, may experience severe reactions associated 
with paradoxical bradycardia, deep hypotension, and severe 
bronchospasm. The difficulty of recovery can occur with both 
antagonists `-1 and `-217(D). Despite this fact, the majority of 
patients using `-blockers do not have their receptors totally 
blocked, and epinephrine should not be avoided in these cases.
Other classes of drugs can also act as factors that increase 
the risk for severe anaphylactic reactions. Angiotensin-
converting enzyme (ACE) inhibitors can interfere with the 
endogenous shock-compensatory mechanism (activation of 
the rennin-angiotensin-aldosterone system), causing pharynx 
and tongue edema, with risk of death18(D). Monoamine-
oxidase inhibitors can increase risks from epinephrine by 
interfering with its degradation.
Recommendation
Advanced age, presence of pre-existing cardiovascular disease, 
asthma, concomitant use of `-blockers, and use of ACE 
inhibitors are associated with risk of more severe reactions.
4. What are the features of fatal anaphylaxis 
clinical picture?
Generally, fatal anaphylactic reactions are characterized by 
symptoms usually limited to a system. Death can occur by 
shock or by cardiorespiratory arrest19(C)20(D).
Death by shock mainly occurs in young individuals with 
healthy hearts. Shock is caused by vasodilation with volume 
redistribution and a drop in venous blood return. Erect posture 
is favorable to fatal evolution21(D).
In elderly individuals or in those pre-existing cardiovascular 
disease, death usually occurs by cardio-respiratory arrest 
caused by arrhythmia, due to the myocardial action of the 
soluble mediators released in the anaphylactic reaction. 
Electrocardiographic changes from myocardial ischemia are 
usually found in anaphylactic shock and may lead to diagnostic 
confusion20(D).
Fatal cases can also occur by cardiorespiratory arrest caused 
by severe bronchospasm (especially in asthmatic patients), or 
by edema in the upper airways, leading to suffocation. Fatal 
anaphylaxis in asthmatic patients is even more related to food 
allergy. Asphyxiation by edema in the upper airways is more 
common in reactions to insects stings and types of food than 
in reaction to drugs22(D) 23(D).
Recommendation
Anaphylaxis is a severe acute allergic reaction and potentially 
fatal.
5. How to investigate the cause of anaphylaxis?
Anaphylaxis diagnosis is usually clinical. Generally, the history 
is  characteristic. Sudden onset of signs and symptoms, such 
as hives, angioedema, diffuse erythema, pruritus, difficulty 
breathing, nausea, vomiting, abdominal colics, hypotension, 
bronchospasm, dizziness, or syncope must lead to the 
suspicion of anaphylactic reaction10,24(D).
The levels of histamine, tryptase, and other mediators rise 
in the acute phase. Histamine is quickly degraded, while the 
levels of tryptase remains elevated for a prolonged time (4 to 
6 hours). Determining serum tryptase levels can be used for 
confirming diagnosis of anaphylaxis25(C)2(D).
In a significant number of cases, the clinical history allows 
for the identification or suspicion of a triggering agent26(D). The 
most common agents are medications, certain types of food, 
and venom of bees, wasps (hornets), and ants. It is important 
to identify cofactors such as infection, physical exercise, and 
alcohol consumption, among others27(A)2,4(D).
The medications most associated with anaphylaxis are 
analgesics, non-steroidal anti-inflammatory drugs, and 
antibiotics. In the surgical environment, neuromuscular 
relaxants, opiates, and other drugs should also be added to 
this list2,26,28(D).
In Brazil, in infants and young children, cow’s milk and 
white egg, followed by fruits and vegetables are the main 
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types of food causing anaphylaxis. In adolescence and 
adult life, hypersensitivity to mollusks and crustaceans is 
predominant2(D) 8(C).
The venom delivered by insect stings can induce allergic 
sensitization and anaphylactic reactions. The main agents 
are bees, wasps (hornets), and ants. Generally, patients report 
having been stung moments before the onset of clinical 
manifestations7,29(C).
Latex contained in gloves, medical products, toys, and 
condoms takes part in some reactions, especially in the 
medical-surgical environment. The triggering of anaphylaxis 
by physical exercise, whether or not associated with previous 
ingestion of certain types of food or medication, has been 
demonstrated. Physical stimuli such as cold weather, dialysis 
products, disinfection agents, and other products can be 
causative agents of anaphylaxis in a lower number of cases2(D).
The identification of allergen-specific IgE antibodies 
can be made by skin prick testing (puncture) for immediate 
reading and by serum. These procedures are useful in 
evaluating allergies to food, to venom of insects, and to 
certain medications8(C)2,26(D). Cutaneous tests performed 
with standardized extracts present more sensitivity and are 
the preferential method of evaluation employed by specialists; 
they must be performed in the hospital environment7(C)2,26(D).
The presence of specific IgE antibodies for a given allergen 
indicates sensitization and it is not necessarily indicative of 
clinical participation30,31(D).
Recommendation
Anaphylaxis diagnosis is usually clinical. Investigation is 
necessary to confirm the diagnostic suspicion, identify 
unknown etiological agents, and direct the prevention of new 
episodes. Complementary exams should be based on clinical 
history.
6. What is the diagnostic procedure in patients 
with anaphylactic reaction to insect sting?
In patients with anaphylactic reaction to insect sting, the 
identification of the insect is important . It is common that the 
patient is able to do so. Bees leave their stinger in the site, but 
wasps act differently. Ants cause a local lesion with erythema 
and blister formation. Usually, the stings cause pain and may 
or not have a reaction on the site32(C)26(D). Occasionally, the 
help of an entomologist can assist in the identification of 
species.
The allergic sensitivity diagnosis is performed by the 
characterization of the presence of specific IgE antibodies to 
the venom of insects. This can be performed by cutaneous 
tests or by determining specific IgE serum. The preferred 
diagnostic method is the skin test with venom, considering 
its high sensitivity and safety. Cutaneous tests are positive in 
65% to 85% of patients with clinical history of systemic reaction 
to hymenoptera stings33,34(D). It is recommendable to respect 
a period of 3 to 4 weeks after the acute episode in order to 
perform diagnostic exams.
Negative cutaneous tests in patients with positive clinical 
history may be caused by loss of sensitivity, if there was a long 
period of time between the event and the test. Negative tests 
can also occur if the reaction was recent, within a refractory 
period of allergy after the systemic reaction. In this situation, 
tests must be repeated at between 3 and 6 months33,34(D).
In adults with negative tests, the chance for reaction to a 
new sting is small (5%) as compared to the risk from 25% to 
70%, when cutaneous tests with venom are positive. Present 
guidelines do not properly approach the question of which 
would be the best treatment to patients with a convincing 
history of acute reaction to insect sting, but with negative 
results as to the research of venom sensitivity35(C) 36(D). In 
complex cases with inconclusive results from diagnostic 
tests, the CD63 activation test is particularly useful and more 
sensitive as compared to intradermal tests, although it is still 
unavailable in this community37(C).
Tryptase serum levels are related to severity of reaction, and 
safety and efficacy of venom immunotherapy . Thus, tryptase 
levels are risk factors to severe anaphylactic reactions by insect 
stings38,39(B).
Patients with severe systemic reactions in which allergic 
sensitivity to venom has been demonstrated, and who are at 
risk of suffering a new sting, are candidates to receive specific 
immunotherapy with insect venom26(D). Immunotherapy 
must not be employed in patients with negative tests to IgE 
antibodies, or with positive tests not correlated with the 
suspected triggering agents40(D).
Recommendation
The preferred diagnostic method is the cutaneous test with venom.
7. What are the main agents of transoperative 
anaphylaxis?
Any of the drugs used during surgeries can induce 
anaphylactic reactions. Neuromuscular blockers, hypnotics, 
antibiotics, opiates, analgesics, anti-inflammatory drugs, 
plasma expanders, dyes, and products containing latex are 
the main triggering agents of anaphylaxis in the surgical 
environment41(D).
The incidence of reactions is variable, from 1:3,500 to 
1:20,00042,43(D). Anaphylaxis diagnosis in the anesthetized 
patient is considered to be more difficult due to the low clinical 
expression in this situation. Thus, constant attention and 
knowledge on the part of the anesthesiologist are extremely 
important42,43(D).
Evaluation by a specialist after an event of surgical 
anaphylaxis aims to identify the causative agent, to find 
a secure option in case of a new procedure, and to guide 
treatment in order to prevent a new episode44,45(D). The 
investigation of surgical anaphylaxis is a delicate procedure 
that requires time and clinical experience. Simultaneous 
exposure to several potential triggering agents is one of the 
factors that make it difficult to identify the causative agent. 
Acute reactions caused by medication occur by mast cells and 
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basophils activation and consequent release of vasoactive 
mediators, such as histamines, leukotrienes, prostaglandins, 
and others. This type of activation can be mediated by an 
immune-specific mechanism, such as the connection between 
allergens and IgE antibodies, or by unspecified activation of 
mast cells and basophils41,44(D).
From the information provided by the surgeon and 
anesthesiologist, a diagnostic conduct is established involving 
laboratory tests and performance of cutaneous tests. Diagnosis 
is based on skin test applications (puncture and intradermal), 
with the chemicals suspected, according to the routines 
defined by various centers46,47(D). In addition, there are 
laboratory trials available for detecting IgE antibodies to certain 
medications and latex41(D).  techniques, which are used to 
identify activation of basophils, have been studied and applied 
to some specialized centers in Europe and in USA, even though 
they have not yet been standardized41(D).
Recommendation
Based on the history of reaction and by using the available 
techniques, it is possible to efficiently evaluate anaphylactic 
reaction in the surgical environment. 
The final diagnosis results from knowledge and clinical 
experience.
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